Early Phase Cancer Immunotherapy
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
CHF 200.50
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Patel, Sandip Pravin (Hrsg.)
- ISBN: 978-3-319-63757-0
- EAN: 9783319637570
- Produktnummer: 24699721
- Verlag: Springer
- Sprache: Englisch
- Erscheinungsjahr: 2017
- Plattform: PDF
- Masse: 5'487 KB
Über den Autor
Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego. Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.
11 weitere Werke von Razelle (Hrsg.) Kurzrock:
Bewertungen
Anmelden